Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...

With excitement of the encouraging data on COVID-19 prophylactic vaccines, let’s not forget the infection rate and mortality are higher than ever, and treatment options are limited. One of the missed opportunities...

The first FDA-authorized at-home COVID-19 test makes it possible for symptomatic patients to get a rapid diagnosis while isolating at home, but is unlikely to open the floodgates to routine self-screening....

It’s been four years since the first CAR T cell therapies were approved and inadequate reimbursement is still a barrier to access in the U.S. A new payment rule proposed by CMS aims to change...

Performance of biotechs valued at over $10 billion was already dwindling throughout 2017 before a flood of disappointing earnings began to roll in for several of the largest companies. In the days since Oct. 19,...

FDA documents concerning the review of Exondys 51 eteplirsen to treat DMD show that the chorus keening that the approval opens the floodgates for companies to combine shoddy, underpowered studies with patient activism to gain...

With new papers published by the day and a flurry of big-dollar deals and financings, it's hard to separate the signal from the noise in the microbiome space. The space has become so hot that...

Gilead Sciences Inc. and AbbVie Inc. continue to vie for preferred coverage of their HCV drugs in the U.S. private payer market, and Gilead is out to an early lead when it comes to total...